264 related articles for article (PubMed ID: 36476851)
21. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
22. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
23. Establishment of multiplex RT-PCR to detect fusion genes for the diagnosis of Ewing sarcoma.
Ueno-Yokohata H; Okita H; Nakasato K; Kiyotani C; Kato M; Matsumoto K; Kiyokawa N; Nakazawa A; Yoshioka T
Diagn Pathol; 2021 Nov; 16(1):102. PubMed ID: 34749732
[TBL] [Abstract][Full Text] [Related]
24. Systems Biology Analysis for Ewing Sarcoma.
Petrizzelli M; Merlevede J; Zinovyev A
Methods Mol Biol; 2021; 2226():303-333. PubMed ID: 33326111
[TBL] [Abstract][Full Text] [Related]
25. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
26. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
28. DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma.
Bayanjargal A; Taslim C; Showpnil IA; Selich-Anderson J; Crow JC; Lessnick SL; Theisen ER
bioRxiv; 2024 Jun; ():. PubMed ID: 38352344
[TBL] [Abstract][Full Text] [Related]
29. Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.
Tsuda Y; Dickson BC; Swanson D; Sung YS; Zhang L; Meyers P; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 May; 59(5):286-294. PubMed ID: 31756779
[TBL] [Abstract][Full Text] [Related]
30. Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors.
Patócs B; Németh K; Garami M; Arató G; Kovalszky I; Szendrői M; Fekete G
Cell Oncol (Dordr); 2013 Jun; 36(3):191-200. PubMed ID: 23494411
[TBL] [Abstract][Full Text] [Related]
31. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.
Riggi N; Knoechel B; Gillespie SM; Rheinbay E; Boulay G; Suvà ML; Rossetti NE; Boonseng WE; Oksuz O; Cook EB; Formey A; Patel A; Gymrek M; Thapar V; Deshpande V; Ting DT; Hornicek FJ; Nielsen GP; Stamenkovic I; Aryee MJ; Bernstein BE; Rivera MN
Cancer Cell; 2014 Nov; 26(5):668-681. PubMed ID: 25453903
[TBL] [Abstract][Full Text] [Related]
32. Ewing sarcoma.
Grünewald TGP; Cidre-Aranaz F; Surdez D; Tomazou EM; de Álava E; Kovar H; Sorensen PH; Delattre O; Dirksen U
Nat Rev Dis Primers; 2018 Jul; 4(1):5. PubMed ID: 29977059
[TBL] [Abstract][Full Text] [Related]
33. Prostatic carcinoma with neuroendocrine differentiation harboring the EWSR1-FEV fusion transcript in a man with the WRN G327X germline mutation: A new variant of prostatic carcinoma or a member of the Ewing sarcoma family of tumors?
Febres-Aldana CA; Krishnamurthy K; Delgado R; Kochiyil J; Poppiti R; Medina AM
Pathol Res Pract; 2020 Feb; 216(2):152758. PubMed ID: 31831298
[TBL] [Abstract][Full Text] [Related]
34. The Transcription Factor
García-García L; Fernández-Tabanera E; Cervera ST; Melero-Fernández de Mera RM; Josa S; González-González L; Rodríguez-Martín C; Grünewald TGP; Alonso J
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830820
[TBL] [Abstract][Full Text] [Related]
35. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
[TBL] [Abstract][Full Text] [Related]
36. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
38. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
Deng Q; Natesan R; Cidre-Aranaz F; Arif S; Liu Y; Rasool RU; Wang P; Mitchell-Velasquez E; Das CK; Vinca E; Cramer Z; Grohar PJ; Chou M; Kumar-Sinha C; Weber K; Eisinger-Mathason TSK; Grillet N; Grünewald TGP; Asangani IA
Cell Rep; 2022 Jun; 39(11):110971. PubMed ID: 35705030
[TBL] [Abstract][Full Text] [Related]
39. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
40. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
